Myc roles in hematopoiesis and leukemia

Genes and Cancer

Volumn 1, Issue 6, 2010, Pages 605-616

  Dolores Delgado, M ^a   León, Javier ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Differentiation; Hematopoietic stem cells; Leukemia; Myc

Indexed keywords

MYC PROTEIN;

ARTICLE; BURKITT LYMPHOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOME TRANSLOCATION; DISEASE COURSE; GENE DELETION; GENE OVEREXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LYMPHOID CELL LINE; LYMPHOMA; MYELOID LEUKEMIA; MYELOID PROGENITOR CELL; NONHUMAN; ONCOGENE C MYB; ONCOGENE C MYC; ONCOGENE MYC; PRIORITY JOURNAL;

AVES; MUS; MUS MUSCULUS;

EID: 79952830167     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910377495     Document Type: Article

References (150)

1. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008;132:631-44.
2. Zon LI. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature 2008;453:306-13.
3. Shizuru JA, Negrin RS, Weissman IL. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med 2005;56:509-38.
4. Kondo M, Wagers AJ, Manz MG, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003;21:759-806.
5. Adams GB, Scadden DT. The hematopoietic stem cell in its place. Nat Immunol 2006;7:333-7.
6. Iwasaki H, Akashi K. Hematopoietic developmental pathways: on cellular basis. Oncogene 2007;26:6687-96.
7. Miranda-Saavedra D, Gottgens B. Transcriptional regulatory networks in haematopoiesis. Curr Opin Genet Dev 2008;18:530-5.
8. Kim SI, Bresnick EH. Transcriptional control of erythropoiesis: emerging mechanisms and principles. Oncogene 2007;26:6777-94.
9. Tsiftsoglou AS, Vizirianakis IS, Strouboulis J. Erythropoiesis: model systems, molecular regulators, and developmental programs. IUBMB Life 2009;61:800-30.
10. Iwasaki H, Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity 2007;26:726-40.
11. Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity 2007;26:715-25.
12. Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev Immunol 2005;23:601-49.
13. Leon J, Ferrandiz N, Acosta JC, Delgado MD. Inhibition of cell differentiation: A critical mechanism for MYC-mediated carcinogenesis? Cell Cycle 2009;8:1148-57.
14. Coppola JA, Cole MD. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature 1986;320:760-3.
15. Prochownik EV, Kukowska J. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation. Nature 1986;322:848-50.
16. Dmitrovsky E, Kuehl WM, Hollis GF, Kirsch IR, Bender TP, Segal S. Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature 1986;322:748-50.
17. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 1986;47:11-8.
18. Delgado MD, Lerga A, Canelles M, Gomez- Casares MT, Leon J. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene 1995;10:1659-65.
19. Lerga A, Crespo P, Berciano M, et al. Regulation of c-Myc and Max in megakaryocytic and monocytic- macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c- Myc is down-regulated but does not inhibit differentiation. Cell Growth Differ 1999;10:639-54.
20. Canelles M, Delgado MD, Hyland KM, et al. Max and inhibitory c-Myc mutants induce erythroid differentiation and resistance to apoptosis in human myeloid leukemia cells. Oncogene 1997;14:1315-27.
21. Acosta JC, Ferrandiz N, Bretones G, et al. Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest. Mol Cell Biol 2008;28:7286-95.
22. Ryan KM, Birnie GD. Cell-cycle progression is not essential for c-Myc to block differentiation. Oncogene 1997;14:2835-43.
23. Gomez-Casares MT, Delgado MD, Lerga A, et al. Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells. Leukemia 1993;7:1824-33.
24. Sheiness D, Bishop JM. DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 1979;31:514-21.
25. Varmus HE. The molecular genetics of cellular oncogenes. Annu Rev Genet 1984;18:553-612.
26. Laurenti E, Varnum-Finney B, Wilson A, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008;3:611-24.
27. Huang CY, Bredemeyer AL, Walker LM, Bassing CH, Sleckman BP. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J Immunol 2008;38:342-9.
28. Reavie L, Gatta GD, Crusio K, et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol 2010;11:207-15.
29. Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL. The purification and characterization of fetal liver hematopoietic stem cells. Proc Natl Acad Sci U S A 1995;92:10302-6.
30. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002;16:2530-43.
31. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 1993;7:671-82.
32. Trumpp A, Refaeli Y, Oskarsson T, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001;414:768-73.
33. He C, Hu H, Braren R, et al. c-myc in the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo. Development 2008;135:2467-77.
34. Dubois NC, Adolphe C, Ehninger A, Wang RA, Robertson EJ, Trumpp A. Placental rescue reveals a sole requirement for c-Myc in embryonic erythroblast survival and hematopoietic stem cell function. Development 2008;135:2455-65.
35. Wilson A, Murphy MJ, Oskarsson T, et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004;18:2747-63.
36. Satoh Y, Matsumura I, Tanaka H, et al. Roles for c-Myc in self-renewal of hematopoietic stem cells. J Biol Chem 2004;279:24986-93.
37. Walkley CR, Fero ML, Chien WM, Purton LE, McArthur GA. Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol 2005;7:172-8.
38. Baena E, Ortiz M, Martinez AC, de Alboran IM. c-Myc is essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-1(+) c-Kit(-) cell generation through p21. Exp Hematol 2007;35:1333-43.
39. Malynn BA, de Alboran IM, O'Hagan RC, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 2000;14:1390-9.
40. Matsuoka S, Oike Y, Onoyama I, et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008;22:986-91.
41. Zimmerman K, Alt FW. Expression and function of myc family genes. Crit Rev Oncog 1990;2:75-95.
42. Dose M, Khan I, Guo Z, et al. c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood 2006;108:2669-77.
43. Smith RK, Zimmerman K, Yancopoulos GD, Ma A, Alt FW. Transcriptional down-regulation of N-myc expression during B-cell development. Mol Cell Biol 1992;12:1578-84.
44. Klemsz MJ, Justement LB, Palmer E, Cambier JC. Induction of c-fos and c-myc expression during B cell activation by IL-4 and immunoglobulin binding ligands. J Immunol 1989;143:1032-9.
45. Larsson LG, Schena M, Carlsson M, Sallstrom J, Nilsson K. Expression of the c-myc protein is down-regulated at the terminal stages during in vitro differentiation of B-type chronic lymphocytic leukemia cells. Blood 1991;77:1025-32.
46. Habib T, Park H, Tsang M, et al. Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol 2007;179:717-31.
47. de Alboran IM, O'Hagan RC, Gartner F, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001;14:45-55.
48. Lindsten T, June CH, Thompson CB. Multiple mechanisms regulate c-myc gene expression during normal T cell activation. EMBO J 1988;7:2787-94.
49. Douglas NC, Jacobs H, Bothwell AL, Hayday AC. Defining the specific physiological requirements for c-Myc in T cell development. Nat Immunol 2001;2:307-15.
50. Dose M, Sleckman BP, Han J, Bredemeyer AL, Bendelac A, Gounari F. Intrathymic proliferation wave essential for Valpha14+ natural killer T cell development depends on c-Myc. Proc Natl Acad Sci U S A 2009;106:8641-6.
51. Mycko MP, Ferrero I, Wilson A, et al. Selective requirement for c-Myc at an early stage of V(alpha)14i NKT cell development. J Immunol 2009;182:4641-8.
52. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996;381:751-8.
53. Scheller H, Tobollik S, Kutzera A, et al. c-Myc overexpression promotes a germinal centerlike program in Burkitt's lymphoma. Oncogene 2010;29:888-97.
54. Guo Y, Niu C, Breslin P, et al. c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Blood 2009;114:2097-106.
55. Niu C, Zhang J, Breslin P, Onciu M, Ma Z, Morris SW. c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development. Blood 2009;114:2087-96.
56. Thompson A, Zhang Y, Kamen D, Jackson CW, Cardiff RD, Ravid K. Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization. J Biol Chem 1996;271:22976-82.
57. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.
58. Schmidt EV, Pattengale PK, Weir L, Leder P. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre- B-cell lymphoma model. Proc Natl Acad Sci U S A 1988;85:6047-51.
59. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999;13:2658-69.
60. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1:289-98.
61. Sheppard RD, Samant SA, Rosenberg M, Silver LM, Cole MD. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors. Oncogene 1998;17:2073-85.
62. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
63. Palomo C, Zou X, Nicholson IC, Butzler C, Bruggemann M. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu). Cancer Res 1999;59:5625-8.
64. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990;55:133-270.
65. Park SS, Kim JS, Tessarollo L, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005;65:1306-15.
66. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 2008;6:e152.
67. Khuda SE, Loo WM, Janz S, Van Ness B, Erickson LD. Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors. J Immunol 2008;181:7537-49.
68. Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst) 2006;5: 1213-24.
69. Skoda RC, Tsai SF, Orkin SH, Leder P. Expression of c-MYC under the control of GATA-1 regulatory sequences causes erythroleukemia in transgenic mice. J Exp Med 1995;181:1603-13.
70. Smith DP, Bath ML, Harris AW, Cory S. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC. Oncogene 2005;24:3544-53.
71. Smith DP, Bath ML, Metcalf D, Harris AW, Cory S. MYC levels govern hematopoietic tumor type and latency in transgenic mice. Blood 2006;108:653-61.
72. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 2005;106:2452-61.
73. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005;436:807-11.
74. Yu D, Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 2002;21:1922-7.
75. Yu D, Allman D, Goldschmidt MH, Atchison ML, Monroe JG, Thomas-Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/ Pax5 pathway. Blood 2003;101:1950-5.
76. Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC. Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res 2007;67:10677-85.
77. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009;28:1274-9.
78. Hirouchi T, Takabatake T, Yoshida K, et al. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice. Exp Hematol 2008;36:871-85.
79. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancerassociated and transforming mutations stabilize Myc. EMBO J 1999;18:717-26.
80. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000;95:2104-10.
81. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000;20:2423-35.
82. Lee JW, Soung YH, Kim SY, et al. Mutational analysis of MYC in common epithelial cancers and acute leukemias. APMIS 2006;114:436-9.
83. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and overview of the calssification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, & Harris NL. et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues (8th ed.). Lyon, France: International Agency for Research on Cancer; 2008. p. 158-66.
84. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010;116:1165-76.
85. Malempati S, Tibbitts D, Cunningham M, et al. Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia 2006;20:1572-81.
86. Cardone M, Kandilci A, Carella C, et al. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol Cell Biol 2005;25:2395-405.
87. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006;6:347-59.
88. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/ lymphoma. Genes Dev 2006;20:2096-109.
89. Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feedforward- loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006;103:18261-6.
90. Sharma VM, Draheim KM, Kelliher MA. The Notch1/c-Myc pathway in T cell leukemia. Cell Cycle 2007;6:927-30.
91. Palomero T, Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res 2008;14:5314-7.
92. Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010;115:2845-51.
93. Yee KW, O'Brien SM. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:1105-29.
94. Chiorazzi N, Allen SL, Ferrarini M. Clinical and laboratory parameters that define clinically relevant B-CLL subgroups. Curr Top Microbiol Immunol 2005;294:109-33.
95. Greil R, Fasching B, Loidl P, Huber H. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood 1991;78:180-91.
96. Scandurra M, Rossi D, Deambrogi C, et al. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. Hematol Oncol 2010;28:62-67.
97. Huh YO, Lin KI, Vega F, et al. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 2008;142:36-44.
98. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082-6.
99. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000;97:228-33.
100. Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 2009;48:624-36.
101. Vardiman JW, Brunning RD, Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues (4th ed.). Lyon, France: International Agency for Research on Cancer; 2008. p. 18-37.
102. Ferrari S, Narni F, Mars W, et al. Expression of growth-regulated genes in human acute leukemias. Cancer Res 1986;46:5162-6.
103. Calabretta B, Venturelli D, Kaczmarek L, et al. Altered expression of G1-specific genes in human malignant myeloid cells. Proc Natl Acad Sci U S A 1986;83:1495-8.
104. Muller-Tidow C, Steffen B, Cauvet T, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004;24:2890-904.
105. Rice KL, Hormaeche I, Doulatov S, et al. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 2009;114:5499-511.
106. Bruyere H, Sutherland H, Chipperfield K, Hudoba M. Concomitant and successive amplifications of MYC in APL-like leukemia. Cancer Genet Cytogenet 2010;197:75-80.
107. Lee S, Kim M, Lim J, et al. Acute myeloid leukemia with MYC amplification in the homogeneous staining regions and double minutes. Cancer Genet Cytogenet 2009;192:96-8.
108. Mathew S, Lorsbach RB, Shearer P, Sandlund JT, Raimondi SC. Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia. Leukemia 2000;14:1314-5.
109. Thomas L, Stamberg J, Gojo I, Ning Y, Rapoport AP. Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) acute myeloid leukemia: two case reports and a review of literature. Am J Hematol 2004;77:55-61.
110. Paulsson K, Lassen C, Kuric N, et al. MYC is not overexpressed in a case of chronic myelomonocytic leukemia with MYC-containing double minutes. Leukemia 2003;17:813-5.
111. Storlazzi CT, Fioretos T, Surace C, et al. MYC containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Hum Mol Genet 2006;15:933-42.
112. Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010;95:597-603.
113. Court EL, Smith MA, Avent ND, et al. DNA microarray screening of differential gene expression in bone marrow samples from AML, non- AML patients and AML cell lines. Leuk Res 2004;28:743-53.
114. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-28.
115. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004;104:3679-87.
116. Stirewalt DL, Meshinchi S, Kopecky KJ, et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 2008;47:8-20.
117. Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res 2001; 61:1178-86.
118. Murphy DJ, Junttila MR, Pouyet L, et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008;14:447-57.
119. Wilda M, Busch K, Klose I, et al. Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus. Genes Chromosomes Cancer 2004;41:178-82.
120. Theophile K, Buesche G, Kreipe H, Bock O. The expression levels of telomerase catalytic subunit hTERT and oncogenic MYC in essential thrombocythemia are affected by the molecular subtype. Ann Hematol 2008;87:263-8.
121. Watanabe S, Itoh T, Arai K. JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocytemacrophage colony-stimulating factor receptor in BA/F3 cells. J Biol Chem 1996;271:12681-6.
122. Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 2002;21:7137-46.
123. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53.
124. Gomez-Casares MT, Vaque JP, Lemes A, Molero T, Delgado MD, Leon J. C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica 2004;89:241-3.
125. Lugo TG, Witte ON. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol 1989;9:1263-70.
126. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70:901-10.
127. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science 1994;264:424-6.
128. Handa H, Hegde UP, Kotelnikov VM, et al. Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase. Leuk Res 1997;21:479-89.
129. Beck Z, Bacsi A, Kovacs E, et al. Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration. Leuk Lymphoma 1998;30:293-306.
130. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 2003;22:3952-63.
131. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007;21:494-504.
132. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-30.
133. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107:76-94.
134. Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46:1039-50.
135. Larsson LG, Ivhed I, Gidlund M, Pettersson U, Vennstrom B, Nilsson K. Phorbol ester-induced terminal differentiation is inhibited in human U-937 monoblastic cells expressing a v-myc oncogene. Proc Natl Acad Sci U S A 1988;85:2638-42.
136. Wu S, Cetinkaya C, Munoz-Alonso MJ, et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003;22: 351-60.
137. Bacon TA, Wickstrom E. Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia HL-60 cells in both serum-containing and serum-free media. Oncogene Res 1991;6:21-32.
138. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol 1988;8:963-73.
139. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006;34:1480-9.
140. Acosta JC, Richard C, Delgado MD, et al. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther 2003;2:893-900.
141. Chisholm O, Stapleton P, Symonds G. Constitutive expression of exogenous myc in myelomonocytic cells: acquisition of a more transformed phenotype and inhibition of differentiation induction. Oncogene 1992;7:1827-36.
142. Nguyen HQ, Selvakumaran M, Liebermann DA, Hoffman B. Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells. Oncogene 1995;11:2439-44.
143. Shafarenko M, Liebermann DA, Hoffman B. Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation. Blood 2005; 106:871-8.
144. Johansen LM, Iwama A, Lodie TA, et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol 2001;21:3789-806.
145. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:318-30.
146. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001;20:5595-610.
147. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220-35.
148. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004;121:384-92.
149. Larramendy ML, Niini T, Elonen E, et al. Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia: a microarray analysis. Haematologica 2002;87:569-77.
150. Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A 2002;99:14925-30.